Sessa W C, Halushka P V, Okwu A, Nasjletti A
Department of Pharmacology, New York Medical College, Valhalla 10595.
Circ Res. 1990 Dec;67(6):1562-9. doi: 10.1161/01.res.67.6.1562.
Recently, we have shown that dexamethasone treatment of rabbits specifically reduces vascular smooth muscle responsiveness to agonists that interact with the vascular thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor. One potential site at which dexamethasone can influence prostanoid-mediated vasoconstriction may be at the level of the vascular TXA2/PGH2 receptor. Therefore, we characterized the vascular TXA2/PGH2 receptor in rabbit aortic membranes and examined the influence of dexamethasone treatment on vascular TXA2/PGH2 receptor affinity and number. The binding of [125I][1S-(1 alpha,2 beta(5Z),3 alpha(1E,3R)4 alpha)]-7-[3-(3- hydroxy-4-(p-iodophenoxy)-1-butenyl)-7-oxabicyclo[2.2.1] heptan-2-yl]-5-heptanoic acid ([125I]BOP), a potent TXA2/PGH2 receptor agonist, to rabbit aortic membranes was saturable, displaceable, and dependent on protein concentration. Scatchard analysis of equilibrium binding data disclosed one class of high affinity binding sites with a Kd of 0.44 +/- 0.13 nM and a Bmax of 114.4 +/- 5.2 fmol/mg protein (n = 7). Removal of the endothelium before membrane preparation did not significantly alter the affinity or number of binding sites for [125I]BOP. Kinetic analysis of the rates of [125I]BOP association/dissociation yielded a Kd of 0.62 nM. The ability of various agonists at the TXA2/PGH2 receptor to displace [125I]BOP from vascular membranes correlated well with their contractile potencies in rabbit aortic rings. Moreover, stereospecific displacement of [125I]BOP binding in aortic membranes and inhibition of U46619-mediated aortic contractions were obtained with the stereoisomers L657925(-) and L657926(+). Collectively, these data suggest that this binding site represents the functionally relevant vascular TXA2/PGH2 receptor. In functional experiments, [127I]BOP induced concentration-dependent contractions of the rabbit aorta, which were reduced by 52% in vessels from dexamethasone-treated rabbits.(ABSTRACT TRUNCATED AT 250 WORDS)
最近,我们已经表明,地塞米松治疗兔子可特异性降低血管平滑肌对与血管血栓素A2/前列腺素H2(TXA2/PGH2)受体相互作用的激动剂的反应性。地塞米松可能影响类前列腺素介导的血管收缩的一个潜在位点可能在血管TXA2/PGH2受体水平。因此,我们对兔主动脉膜中的血管TXA2/PGH2受体进行了表征,并研究了地塞米松治疗对血管TXA2/PGH2受体亲和力和数量的影响。[125I][1S-(1α,2β(5Z),3α(1E,3R)4α)]-7-[3-(3-羟基-4-(对碘苯氧基)-1-丁烯基)-7-氧杂双环[2.2.1]庚烷-2-基]-5-庚酸([125I]BOP),一种有效的TXA2/PGH2受体激动剂,与兔主动脉膜的结合是可饱和的、可置换的,并且依赖于蛋白质浓度。对平衡结合数据的Scatchard分析揭示了一类高亲和力结合位点,其Kd为0.44±0.13 nM,Bmax为114.4±5.2 fmol/mg蛋白质(n = 7)。在制备膜之前去除内皮并没有显著改变[125I]BOP的结合位点亲和力或数量。对[125I]BOP结合/解离速率的动力学分析得出Kd为0.62 nM。TXA2/PGH2受体上各种激动剂从血管膜上置换[125I]BOP的能力与其在兔主动脉环中的收缩效力密切相关。此外,用立体异构体L657925(-)和L657926(+)获得了主动脉膜中[125I]BOP结合的立体特异性置换以及U46619介导的主动脉收缩的抑制。总的来说,这些数据表明该结合位点代表功能相关的血管TXA2/PGH2受体。在功能实验中,[127I]BOP诱导兔主动脉的浓度依赖性收缩,在用地塞米松治疗的兔子的血管中这种收缩减少了52%。(摘要截短至250字)